These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 12396603)

  • 21. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine.
    Cafaro A; Caputo A; Fracasso C; Maggiorella MT; Goletti D; Baroncelli S; Pace M; Sernicola L; Koanga-Mogtomo ML; Betti M; Borsetti A; Belli R; Akerblom L; Corrias F; Buttò S; Heeney J; Verani P; Titti F; Ensoli B
    Nat Med; 1999 Jun; 5(6):643-50. PubMed ID: 10371502
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IFN alpha kinoid vaccine in conjunction with tritherapy, a weapon to combat immunopathogenesis in AIDS.
    Bizzini B; Volpato I; Lachgar A; Cohen P; Gringeri A
    Biomed Pharmacother; 1999 Mar; 53(2):87-9. PubMed ID: 10337462
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tat toxoid: its potential role as an HIV vaccine.
    Lambert J
    J Hum Virol; 1998; 1(4):249-50. PubMed ID: 10195248
    [No Abstract]   [Full Text] [Related]  

  • 24. AIDS. Escape from the immune system.
    Walker BD; Goulder PJ
    Nature; 2000 Sep; 407(6802):313-4. PubMed ID: 11014174
    [No Abstract]   [Full Text] [Related]  

  • 25. Erythrocytes deliver Tat to interferon-gamma-treated human dendritic cells for efficient initiation of specific type 1 immune responses in vitro.
    Corinti S; Chiarantini L; Dominici S; Laguardia ME; Magnani M; Girolomoni G
    J Leukoc Biol; 2002 Apr; 71(4):652-8. PubMed ID: 11927652
    [TBL] [Abstract][Full Text] [Related]  

  • 26. "Kinoids": the basis for anticytokine immunization and their use in HIV infection.
    Bizzini B; Achour A
    Cell Mol Biol (Noisy-le-grand); 1995 May; 41(3):351-6. PubMed ID: 7580827
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Experimental gene therapy: the transfer of Tat-inducible interferon genes protects human cells against HIV-1 challenge in vitro and in vivo in severe combined immunodeficient mice.
    Sanhadji K; Leissner P; Firouzi R; Pelloquin F; Kehrli L; Marigliano M; Calenda V; Ottmann M; Tardy JC; Mehtali M; Touraine JL
    AIDS; 1997 Jul; 11(8):977-86. PubMed ID: 9223731
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A combination HIV vaccine based on Tat and Env proteins was immunogenic and protected macaques from mucosal SHIV challenge in a pilot study.
    Ferrantelli F; Maggiorella MT; Schiavoni I; Sernicola L; Olivieri E; Farcomeni S; Pavone-Cossut MR; Moretti S; Belli R; Collacchi B; Srivastava IK; Titti F; Cafaro A; Barnett SW; Ensoli B
    Vaccine; 2011 Apr; 29(16):2918-32. PubMed ID: 21338681
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New finding on immune response to HIV Tat may contribute to vaccine, treatment.
    James JS
    AIDS Treat News; 2000 Sep; (351):4. PubMed ID: 12173551
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibody to HIV-1 Tat protein, a key molecule in HIV-1 pathogenesis. A brief review.
    Re MC; Gibellini D; Vitone F; La Placa M
    New Microbiol; 2001 Apr; 24(2):197-205. PubMed ID: 11346305
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HIV-1 Tat protein as a potential AIDS vaccine.
    Goldstein G
    Nat Med; 1996 Sep; 2(9):960-4. PubMed ID: 8782444
    [No Abstract]   [Full Text] [Related]  

  • 32. IFN-gamma induces endothelial cells to proliferate and to invade the extracellular matrix in response to the HIV-1 Tat protein: implications for AIDS-Kaposi's sarcoma pathogenesis.
    Fiorelli V; Barillari G; Toschi E; Sgadari C; Monini P; Stürzl M; Ensoli B
    J Immunol; 1999 Jan; 162(2):1165-70. PubMed ID: 9916748
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cynomolgus macaques immunized with two HIV-1 Tat stabilized proteins raise strong and long-lasting immune responses with a pattern of Th1/Th2 response differing from that in mice.
    Turbant S; Martinon F; Moine G; Le Grand R; Léonetti M
    Vaccine; 2009 Aug; 27(39):5349-56. PubMed ID: 19607953
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design and characterization of an HIV-1 Tat mutant: inactivation of viral and cellular functions but not antigenicity.
    Mayol K; Munier S; Beck A; Verrier B; Guillon C
    Vaccine; 2007 Aug; 25(32):6047-60. PubMed ID: 17604883
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibodies against a multiple-peptide conjugate comprising chemically modified human immunodeficiency virus type-1 functional Tat peptides inhibit infection.
    Devadas K; Boykins RA; Hewlett IK; Wood OL; Clouse KA; Yamada KM; Dhawan S
    Peptides; 2007 Mar; 28(3):496-504. PubMed ID: 17188401
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Avoiding deceptive imprinting of the immune response to HIV-1 infection in vaccine development.
    Muller S
    Int Rev Immunol; 2004; 23(5-6):423-36. PubMed ID: 15370274
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of human immunodeficiency virus type 1 tat from a replication-deficient herpes simplex type 1 vector induces antigen-specific T cell responses.
    Bozac A; Berto E; Vasquez F; Grandi P; Caputo A; Manservigi R; Ensoli B; Marconi P
    Vaccine; 2006 Nov; 24(49-50):7148-58. PubMed ID: 16884834
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A synthetic HIV-1 Tat protein breaches the skin barrier and elicits Tat-neutralizing antibodies and cellular immunity.
    Partidos CD; Moreau E; Chaloin O; Tunis M; Briand JP; Desgranges C; Muller S
    Eur J Immunol; 2004 Dec; 34(12):3723-31. PubMed ID: 15549730
    [TBL] [Abstract][Full Text] [Related]  

  • 39. mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients.
    Van Gulck E; Vlieghe E; Vekemans M; Van Tendeloo VF; Van De Velde A; Smits E; Anguille S; Cools N; Goossens H; Mertens L; De Haes W; Wong J; Florence E; Vanham G; Berneman ZN
    AIDS; 2012 Feb; 26(4):F1-12. PubMed ID: 22156965
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pronounced acute immunosuppression in vivo mediated by HIV Tat challenge.
    Cohen SS; Li C; Ding L; Cao Y; Pardee AB; Shevach EM; Cohen DI
    Proc Natl Acad Sci U S A; 1999 Sep; 96(19):10842-7. PubMed ID: 10485913
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.